A novel therapeutic option in Cogan diseases? TNF-alpha blockers.
Cogan's syndrome is characterized by noninfectious, interstitial keratitis combined with a vestibulo-auditory deficit. Despite therapy with corticosteroids in combination with immunosuppressive agents, relapses occurred in two subjects and the clinical course suggested a progression of the disease. Treatment with anti-TNF-alpha was started leading to a rapid and sustained clinical remission for over 2 respectively 3 years.
Fricker
M
M
Division of Allergology, Policlinics of Allergy and Immunology, Department of Rheumatology and Clinical Immunology/Allergology, University Hospital (Inselspital), Bern, Switzerland.
Baumann
A
A
Wermelinger
F
F
Villiger
P M
PM
Helbling
A
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006312:Hearing Loss, Bilateral / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D010031:Otitis / Q000188:drug therapy*; D012074:Remission Induction; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013577:Syndrome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab